Gilead Sciences Balance Sheet
NASDAQ: GILDHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Gilead Sciences financial position
At the end of fiscal 2025, Gilead Sciences reported total assets of $59.02 billion, up 0.0% from a year earlier against total liabilities of $36.41 billion. Shareholders' equity stood at $22.70 billion, or 38.5% of assets. The company held $7.56 billion in cash and equivalents against $24.94 billion of debt, a net debt position of $17.37 billion.
The current ratio (current assets divided by current liabilities) was 1.55, meaning short-term assets cover obligations due within a year. Debt-to-equity was 1.10.
Summary generated from market data by MetaCap's automated system. Methodology
Gilead Sciences balance sheet (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 7.56B | 9.99B | 6.08B | 5.41B | 5.34B | 6.00B | 11.63B | 17.94B | 7.59B | 8.23B |
| Short-Term Investments | 68.00M | 0 | 1.18B | 973.00M | 1.18B | 1.41B | 12.72B | 12.15B | 17.92B | 3.67B |
| Receivables | 4.91B | 4.42B | 4.66B | 4.78B | 4.49B | 4.89B | 3.58B | 3.33B | 3.85B | 4.51B |
| Inventory | 1.77B | 1.71B | 1.79B | 1.51B | 1.62B | 1.68B | 922.00M | 814.00M | 801.00M | 1.59B |
| Total Current Assets | 18.34B | 19.17B | 16.09B | 14.44B | 14.77B | 16.00B | 30.30B | 35.84B | 31.82B | 19.59B |
| Property, Plant & Equipment | 5.61B | 5.41B | 5.32B | 5.47B | 5.12B | 4.97B | 4.50B | 4.01B | 3.29B | 2.87B |
| Goodwill | 8.31B | 8.31B | 8.31B | 8.31B | 8.33B | 8.11B | 4.12B | 4.12B | 4.16B | 1.17B |
| Intangible Assets | 16.98B | 19.95B | 26.45B | 28.89B | 33.45B | 33.13B | 13.79B | 15.74B | 17.10B | 8.97B |
| Long-Term Investments | 2.97B | 0 | 1.16B | 1.25B | 1.31B | 502.00M | 1.49B | 1.42B | 11.18B | 20.48B |
| Total Assets | 59.02B | 58.99B | 62.13B | 63.17B | 67.95B | 68.41B | 61.63B | 63.67B | 70.28B | 56.98B |
| Accounts Payable | 715.00M | 833.00M | 550.00M | 905.00M | 705.00M | 844.00M | 713.00M | 790.00M | 814.00M | 1.21B |
| Short-Term Debt | 2.81B | 1.81B | 1.80B | 2.27B | 1.52B | 2.76B | 2.50B | 2.75B | 2.75B | 0 |
| Total Current Liabilities | 11.81B | 12.00B | 11.28B | 11.24B | 11.61B | 11.40B | 9.76B | 10.61B | 11.63B | 9.22B |
| Long-Term Debt | 22.13B | 24.90B | 23.19B | 22.96B | 25.18B | 28.64B | 22.09B | 24.57B | 30.80B | 26.35B |
| Total Liabilities | 36.41B | 39.75B | 39.38B | 41.96B | 46.89B | 50.19B | 38.98B | 42.14B | 49.78B | 37.61B |
| Shareholders' Equity | 22.70B | 19.33B | 22.83B | 21.24B | 21.07B | 18.20B | 22.52B | 21.39B | 20.44B | 18.89B |
| Retained Earnings | 13.73B | 11.50B | 16.30B | 15.69B | 16.32B | 14.38B | 19.39B | 19.02B | 19.01B | 18.15B |
| Total Debt | 24.94B | 26.71B | 24.99B | 25.23B | 26.70B | 31.40B | 24.59B | 27.32B | 33.54B | 26.35B |
| Net Cash (Debt) | -17.30B | -16.72B | -17.72B | -18.84B | -20.18B | -23.99B | -241.00M | 2.77B | -8.03B | -14.45B |
| Shares Outstanding | 1.24B | 1.25B | 1.25B | 1.25B | 1.25B | 1.25B | 1.27B | 1.28B | 1.31B | 1.31B |
This table shows 10 annual periods of Gilead Sciences's balance sheet, from FY 2025 back to FY 2016, across 20 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow GILD's reporting calendar. What is a balance sheet?